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Accumulating evidence suggests that Tourette’s Syndrome (TS) – a multifactorial
pediatric disorder characterized by the recurrent exhibition of motor tics and/or vocal
utterances – can partly depend on immune dysregulation provoked by early repeated
streptococcal infections. The natural and adaptive antibody-mediated reaction to
streptococcus has been proposed to potentially turn into a pathological autoimmune
response in vulnerable individuals. Specifically, in conditions of increased permeability of
the blood brain barrier (BBB), streptococcus-induced antibodies have been proposed
to: (i) reach neuronal targets located in brain areas responsible for motion control; and
(ii) contribute to the exhibition of symptoms. This theoretical framework is supported by
indirect evidence indicating that a subset of TS patients exhibit elevated streptococcal
antibody titers upon tic relapses. A systematic evaluation of this hypothesis entails
preclinical studies providing a proof of concept of the aforementioned pathological
sequelae. These studies shall rest upon individuals characterized by a vulnerable immune
system, repeatedly exposed to streptococcus, and carefully screened for phenotypes
isomorphic to the pathological signs of TS observed in patients. Preclinical animal
models may thus constitute an informative, useful tool upon which conducting targeted,
hypothesis-driven experiments. In the present review we discuss the available evidence
in preclinical models in support of the link between TS and pediatric autoimmune
neuropsychiatric disorders associated with streptococcus infections (PANDAS), and
the existing gaps that future research shall bridge. Specifically, we report recent
preclinical evidence indicating that the immune responses to repeated streptococcal
immunizations relate to the occurrence of behavioral and neurological phenotypes
reminiscent of TS. By the same token, we discuss the limitations of these studies: limited
evidence of behavioral phenotypes isomorphic to tics and scarce knowledge about
the immunological phenomena favoring the transition from natural adaptive immunity
to pathological outcomes.
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INTRODUCTION
Neuropsychiatric and neurological disorders are among the
leading causes of disability worldwide (Silberberg et al., 2015).
Several studies reported that people affected by neuropsychiatric
illnesses show a set of psychosocial disturbances, ranging
from difficulties in social interactions to emotional instability
(Hartley et al., 2014; Cieza et al., 2015), ultimately resulting
in difficulties in routine activities (Coenen et al., 2016). Since
neuropsychiatric illnesses have a strong impact on the well-
being of affected individuals, understanding the etiology of
these diseases may beget remarkable heuristic advancements.
Within this framework, epidemiological, clinical, and preclinical
studies reveal that different determinants contribute to the
pathogenesis of neuropsychiatric diseases. Among them, genetic
factors (Hyman, 2008) and several environmental risk factors,
such as prenatal and perinatal injuries or stressors (Bronson and
Bale, 2016) and infectious phenomena (John et al., 2015), play a
key role.
Autoimmunity, defined by Davison as “the failure of an
organism to recognize its own part as self, resulting in a series of
immunological responses to its own cells and tissues” (Davison,
2012) has emerged as a potential pathogenic factor in different
types of neuropsychiatric illnesses, including autoimmune
encephalitis (Höftberger, 2015), systemic lupus erythematosus
(SLE; Podolska et al., 2015), or schizophrenia (Margari et al.,
2013). Infectious phenomena constitute a vulnerability factor
in the onset of autoimmune disorders. In particular, infections
may trigger the onset of autoimmune diseases in the presence
of vulnerability conditions. With respect to neuropsychiatric
disorders, these vulnerability conditions are represented, for
example, by an abnormal permeability of the blood brain
barrier (BBB; Almutairi et al., 2016). Hornig (2013) proposed
that microbes may contribute to the etiology of autoimmune
neurological and neuropsychiatric disorders by triggering the
production of autoantibodies that directly bind brain targets.
In susceptible individuals, these phenomena can result in
the appearance of behavioral and neurochemical abnormalities
(Hornig, 2013).
Within this framework, streptococcal infections have been
linked to a series of neuropsychiatric and movement disorders
(Swedo et al., 1998). For example, different studies documented
that the onset of Sydenham Chorea (SC), a variant of
rheumatic fever, is linked to group A β-hemolitic streptococcus
infections (Swedo et al., 1993; Cardoso et al., 1999). SC is
characterized by choreiform movements that typically involve
face and extremities and, in some cases, by behavioral difficulties
and emotional liability (Swedo et al., 1989; Marques-Dias
et al., 1997). Besides SC, several authors proposed that
streptococcus infections may constitute an etiological factor also
in a series of illnesses that typically arise during childhood.
In particular, Swedo and colleagues proposed the acronym
PANDAS (Pediatric Autoimmune Neuropsychiatric Disorder
Associated with Streptococcal infections) to define a series
of neurological and psychiatric disorders characterized by the
presence of antibodies produced in response to group A β-
hemolytic streptococcus infections (Swedo et al., 1998). The
diagnostic criteria for PANDAS include: prepubertal onset;
obsessive compulsive disorder (OCD) or chronic tic disorder;
relapsing-remitting course of the disease; motor hyperactivity
or reduced fine motor coordination; onset of the disease
or symptoms exacerbation temporally related to streptococcal
infection (Swedo et al., 1998).
In PANDAS and SC, antibodies produced in response to
streptococcus have been proposed to be pathogenic in CNS in
the context of an increased BBB permeability. Since the BBB is
the primary protective barrier for neurons in central nervous
system (CNS), BBB dysfunctions may contribute to the etiology
of several neuropsychiatric disorders (Almutairi et al., 2016). In
particular, in PANDAS and SC, after crossing the damaged BBB,
cross-reactive antibodies may bind specific brain targets at the
level of Basal Ganglia (BG), a brain structure involved in motor
control (Martino et al., 2009; Murphy et al., 2010; Cutforth et al.,
2016).
Streptococcal infections have also been suggested to relate
to Tourette’s Syndrome (TS), a multifactorial and complex
disorder that may, in some cases, match the criteria for PANDAS
(Hoekstra et al., 2013). TS is a childhood-onset disorder, in
which chronic motor or phonic tics are the main symptoms.
Tics are considered chronic if persist over a period longer
than 12 months (Lombroso and Scahill, 2008). Tic, according
to the DSM-5, is defined as “a sudden, rapid, recurrent, non-
rhythmic motor movement or vocalization” (APA, 2013). TS
is more frequent in males than females, with a ratio of 4:1.
Typically, symptoms occur during prepubertal age, between 5
and 7 years, and have a waxing and waning course (Lombroso
and Scahill, 2008). A gradual increase in tic frequency and
severity is generally shown until 8–12 years, while a relevant
reduction occurs in most patients at the end of adolescence
(Leckman et al., 2010). Co-morbid conditions are typical in
TS. In particular, obsessive-compulsive disorder (OCD) and
attention-deficit/hyperactivity disorder (ADHD) are the most
common comorbidities (Leckman et al., 2010). The pathogenesis
of TS is multifactorial, and include genetic vulnerability (Deng
et al., 2012), and several environmental risk factors such
as prenatal and perinatal stressors or injuries and bacterial
and viral infections (Leckman et al., 1987, 1990; Leckman
and Peterson, 1993). With respect to precocious vulnerability,
maternal factors (genetic or environmental) have been shown to
increase individual vulnerability to TS. For example, Dalsgaard
et al. (2015) recently reported that maternal autoimmune
diseases significantly increase vulnerability to TS in the progeny
(Dalsgaard et al., 2015).
While maternal autoimmunity can influence vulnerability to
TS, it is yet to be determined whether these effects are genetic
or environmental. With respect to genetic predispositions,
several authors identified a series of genes for which a direct
contribution to TS can be reasonably proposed. Thus, genetic
linkage, cytogenetics and molecular genetic studies allowed
identifying a set of genes potentially involved in TS (State, 2011).
Among them, contactin-associated protein-like 2 (CNTNAP2),
SLIT and NTRK-like 1 (SLITRK1) or membrane peptidase
2 like (IMMP2L) have been proposed as vulnerability genes.
The proteic product of IMMP2L gene is a peptide with a
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catalytic function that, in the dysfunctional form, may cause
the activation of the cell apoptotic mechanism through an
aberrant mithocondrial functionality (Ma et al., 2011). Several
authors reported in some members of a family with TS the
presence of a translocation between chromosome 7 and 18 that
causes the disruption of IMMP2L gene (Boghosian-Sell et al.,
1996; Petek et al., 2001). However, the role of this gene in
TS etiology remains unclear. CNTNAP2 is a transmembrane
protein of the family of neurexin, abundantly expressed at
the level of the axonal nodes of Ranvier, where it plays a
crucial role in the cell-cell interaction. Poliak et al. (1999),
hypothesized that this peptide may be involved in the positioning
of K+ voltage-gated channel at the level of juxtaparanode
region (Poliak et al., 1999). Verkerk et al. (2003) observed a
chromosomal translocation between chromosome 2 and 7, in the
region encoding CNTNAP2 protein, in a family of TS patients
(Verkerk et al., 2003). The disruption of this region has been
proposed to affect brain areas involved in motor control, thereby
being responsible for the onset of tics (Verkerk et al., 2003).
SLTRK1 is a member of a gene family that encodes a series
of transmembrane proteins. The proteic product of SLTRK1
gene is a peptide that contains two leucine-rich repeat (LRR)
motive and an intracellular C terminus having similarities with
the tropomyosin-related kinase (Trk) neurotrophin’s receptor
(Aruga and Mikoshiba, 2003). SLTRK1 favors the formation of
synapses, neuritic outgrowth and neuronal survival (Kajiwara
et al., 2009). SLTRK1 transcription is regionally regulated in
CNS; the pattern of expression is conserved among different
mammalian species, such as mouse, rhesus monkey and human,
and shows a preferential expression in brain areas involved
in motor control, such as cortex, thalamus and basal ganglia
(Stillman et al., 2009). In particular, SLRTK1 is expressed in
the body compartment of cortex pyramidal projection neurons
during adult life, and is preferentially associated, in the striatum,
with neurons of the direct circuit expressing substance P and
dopamine receptor D1, that project to substantia nigra (SN)
and to globus pallidus (GP; Stillman et al., 2009). Some TS
patients showed a missense mutation at the level of 3′ UTR of
the SLTRK1 gene; this mutation leads to the production of a
protein with an altered capacity of binding the microRNA 189
(Abelson et al., 2005). Moreover, an inversion in chromosome
13 in proximity of the region of the gene has been reported in
patients with TS and ADHD (Proenca et al., 2011). Recently,
Ercan-Sencicek et al. (2010) proposed that a mutation of the
gene encoding for histidine decarboxylase (HDC) constitutes
a rare genetic cause in TS (Ercan-Sencicek et al., 2010). In
particular, the authors identified, through a study of a 2-
generation pedigree in a family with a high incidence of TS, a rare
segregating non-sense mutation in the l-hystidine decarboxylase
(hdc) gene (Ercan-Sencicek et al., 2010). HDC is an enzyme
necessary for the synthesis of histamine (HA) which, in turn, has
been hypothesized to modulate DA level in CNS (Haas et al.,
2008). Subsequently, a reduced concentration of HA in CNS
(caused by the non-sense hdc gene mutation) may result in an
altered dopaminergic regulation at the level of the basal ganglia
circuitry, thereby resulting in TS symptomatology (Castellan
Baldan et al., 2014). In the same study, Castellan Baldan
and collaborators translated this evidence in an experimental
model (hdc knock-out mice, see discussion for additional
details). Moreover, an analysis of rare copy number variants
in TS conducted on 460 patients, revealed the presence of
a significant enrichment of genes involved in histaminergic
pathways (Fernandez et al., 2012). In particular, the authors
reported an enrichment in striatum and cortex of HA coupled
G receptors H2 and H3. Those receptors are located both
presinaptically and postsinaptically: presynaptic HA receptors
are involved in the regulation not only of HA transmission,
but also of dopamine (Fernandez et al., 2012). It is thus
tenable to propose that dysfunctions in histaminergic pathway
may contribute to the onset of TS through the modulation of
dopaminergic transmission.
GAS infections, occurring after TS onset, have been proposed
as a vulnerability factor potentially exacerbating symptoms
(Martino et al., 2009; Landau et al., 2012). Additionally,
in line with the possibility that altered immune capability
constitutes a predisposing factor, clinical data support an
increased vulnerability of the immune system in TS patients.
For example, whilst Bos-Veneman et al. (2011) observed that
TS children were characterized by decreased levels of IgG3
(Bos-Veneman et al., 2011), Kawikova et al. (2007) observed
reduced concentrations of regulatory T cells in TS patients
compared to controls (Kawikova et al., 2007). Moreover, during
tic exacerbations, TS patients showed increased concentrations
of cytokines, interleukin 12 (IL-12) and tumor necrosis factor
alpha (TFN-α) in serum (Leckman et al., 2005; Martino et al.,
2015). Several authors reported the presence of peripheral anti-
streptococcal antibodies and anti-BG antibodies in patients
affected by TS. For example, Cardona and Orefici observed that
a large cohort of TS patients showed significantly higher levels
of anti-streptococcal antibodies compared to control subjects;
moreover, they reported that those patients had previously
been exposed to streptococcal infections (Cardona and Orefici,
2001). Similarly, Rizzo and colleagues reported remarkably
higher concentrations of anti-streptococcal antibody titers and a
significantly higher presence of anti-BG antibodies in TS patients
compared to control subjects (Rizzo et al., 2006). Martino and
colleagues reported a similar increase in anti-BG antibodies in
TS patients compared to controls (Martino et al., 2011).
Although these studies support the existence of a link between
streptococcal infections and TS, several other studies failed to
identify a direct link between immunization and TS symptoms
(Singer et al., 2005a; Dale et al., 2006; Morris et al., 2009; Brilot
et al., 2011). In particular, Singer et al. (2005a) performed ELISA
and Western blot analyses against several epitopes present in
the CNS (e.g., human postmortem caudate, putamen, prefrontal
cortex) with sera obtained from PANDAS and TS patients,
and controls. The authors did not detect differences in serum
autoantibodies among groups (Singer et al., 2005a). Similarly,
Morris et al. (2009), using a different experimental approach
(immunofluorescence), failed to observe any difference among
PANDAS and TS patients, and controls in terms of serum anti-
striatal antibody reactivity (Morris et al., 2009). Finally, Brilot
et al. (2011) reported the presence of serum autoantibodies
capable of binding neuronal cell surface in SC patients, but not
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in PANDAS or TS patients (Brilot et al., 2011). These results
demonstrate that the presence of autoimmune phenomena is
neither a necessary nor a sufficient condition in the etiology of
TS. However, the evidence discussed above indicates that a subset
of TS cases may be dependent on autoimmune phenomena.
Moreover, as already discussed, some cases of TS match
criteria for PANDAS, suggesting that these two disorders may
share — in specific circumstances — analogous etiopathological
mechanisms.
Preclinical experimental models may constitute a valuable
complement to clinical studies whereby they can aid the
comprehension of the fundamental mechanisms favoring disease
onset. Animal models may allow testing different hypotheses
regarding the role exerted by variable factors in the onset and
course of a given disease, and to design innovative therapeutic
approaches (Rickard, 2004; van der Staay, 2006; van der Staay
et al., 2009). Within this framework, several aspects of TS
(symptomatology, genetic predisposition and environmental risk
factors) have been translated into preclinical animal models
(Hallett et al., 2000; Yaddanapudi et al., 2010; Brimberg et al.,
2012; Macrì et al., 2015; see Macrì et al., 2013 for a detailed
review).
Here, we will review preclinical data suggesting a link between
autoimmunity and neurological diseases. In particular, we will
discuss empirical evidence supporting the connection between
TS and PANDAS, and the gaps of these studies that shall be filled
in the future. Finally, in the light of the role of immunity in
the onset of psychiatric disturbance, we discuss the possibility
that peripheral autoantibodies may constitute an innovative
biomarker of diagnostic use (Giana et al., 2015).
PRECLINICAL ANIMAL MODELS AND
AUTOIMMUNITY
Animal models constitute an important tool to aid the
understanding of a given pathology and to potentially
inform innovative therapeutic avenues. Thus, preclinical
experimental models allow dissecting a given phenomenon into
its fundamental determinants (e.g., genetic vs. environmental
predisposing factors) and addressing the role that each of them
plays, either in isolation or in combination with each other. The
development of disease-related animal models rests upon several
stages: the generation of a disease model based on a theoretical
construct, the identification of abnormalities isomorphic to the
symptoms observed in the patient population and the study
of the efficacy of pharmacological treatments. The validity of
each of these stages can be systematically scrutinized. Willner
proposed three validity criteria: construct, face, and predictive
validity (Willner, 1984).
Construct validity can be defined as the etiological similarity
between the disease in human population and the experimental
approach attempting to model such disease.
Face validity relates to the degree of similarity between the
symptoms identified in the disorder examined and the phenotype
(e.g., behavioral, physiological, immunological, neurobiological)
in the experimental model (Willner and Mitchell, 2002). To
fulfill this criterion, a valid animal model shall resemble the
symptomatology observed in humans (van der Staay et al., 2009).
Predictive validity pertains to the therapeutic efficacy of
available treatments. Specifically, to possess an elevated degree of
predictive validity, a given experimental disease model shall be
sensitive to the same available therapeutic approaches adopted in
the patients (Willner, 1984).
Within this framework, the use of preclinical models
has been extensively applied to the study of autoimmune
neurological disorders (see Levite, 2014 and Hornig and Lipkin,
2013 for detailed reviews). Several preclinical animal models
have been developed to address the link between circulating
natural antibodies (directed against specific brain targets),
and behavioral and neurochemical abnormalities. For example,
mice immunized with GluR1 peptide fragments (a subunit of
glutamate AMPA receptors) showed a significant elevation in
circulating anti-GluR1 antibodies, marked hyperactivity, and
increased self-grooming (Capone et al., 2008), the latter being
associated with repetitive behavior (Kalueff et al., 2016). Also,
mice immunized with dopamine transporter (DAT) fragments,
displayed spontaneous hyperactivity, reduced cognitive flexibility
and impulse control in operant behavioral paradigms. Moreover,
the immunization protocol caused, as expected, an elevation in
antibodies targeting dopamine transporter and a variation in
brain striatal concentrations of dopamine and its metabolites
(Adriani et al., 2012).
Glutamate is the main excitatory neurotransmitter in CNS
(Platt, 2007) and is crucial for several neuronal functions.
Abnormalities in glutamatergic neurotransmission have been
shown to directly contribute to CNS disorders (Scoriels et al.,
2015). The overactivation of glutamate receptors (excitotoxicity),
induced by the excess of glutamate, may result in brain damage
and neuronal death (Meldrum, 2000). Besides excitotoxicity,
several types of anti-glutamate receptors antibodies are capable
of inducing pathological effects in CNS (Levite, 2014). These
autoantibodies emerged as one of the most widespread and
dangerous pathogenic agents in CNS, causing impaired neuronal
signaling and brain damages and contributing to the onset of a
series of neuropsychiatric disorders (Levite, 2014). For example,
patients affected by epilepsy and SLE, showed antibodies directed
to different types of glutamate receptors, anti AMPA-GluR3B
(Ganor et al., 2004, 2005a,b,c; Goldberg-Stern et al., 2014)
and anti NMDA-NR2 (Borchers et al., 2005; Asano et al.,
2013; Fanouriakis et al., 2013). From a translational perspective,
antibodies against the same glutamate receptors have been shown
to favor the onset of behavioral and neurochemical alterations
also in preclinical models (see Levite, 2014 for a detailed review).
These results have been observed in conditions of an increased
permeability of the BBB (Kowal and Diamond, 2012). Several
authors reported increased levels of anti-GluR3B antibodies in
different mouse strains (specifically directed against peptide B of
subunit R3 of glutamate AMPA receptors) after immunization
with GluR3B peptide (Levite et al., 1999; Levite and Hermelin,
1999; Ganor et al., 2014). Specifically, Ganor et al. (2014) reported
that DBA/2J mice (genetically epilepsy-prone mice) developed
elevated titers of GluR3B antibodies after immunization with
GluR3B peptide emulsified in Complete Freund’s adjuvant
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(CFA). The presence of these antibodies aggravated seizures
induced by the administration of a chemoconvulsant agent,
and caused abnormal behaviors in mice. With respect to
behavioral alterations, the authors observed, in mice positive to
GluR3B antibodies, increased anxiety-like behaviors and motor
impairments (problems in balance, motor coordination and
muscle strength) compared to mice that did not show GluR3B
antibodies in serum (Ganor et al., 2014).
Kowal and colleagues developed an immune-mediated mouse
model of SLE (Kowal et al., 2004). These authors reported
that the immunization of BALB/C mice with DNA peptide
mimotope, arrayed as an octamer on a polylysine backbone
(MAP peptide), induced the production of antibodies against
subunit NR2 of NMDA glutamate receptor, associated with
neuronal damages and cognitive impairments. In particular,
following the administration of lipopolysaccharide (LPS, a
procedure known to increase the permeability of the BBB) to
immunized mice, NR2 antibodies bound neurons preferentially
in hippocampus, inducing neuronal death and impaired memory
(Kowal et al., 2004). NMDA-NR2 receptors are expressed
throughout the brain, but at highest density within hippocampus,
hypothalamus, and amygdala. When the BBB damage was
induced in mice by epinephrine administration, Huerta et al.
(2006) showed that anti-NR2 antibodies bound preferentially
amygdala’s neurons. Accordingly, immunized mice showed
alteration in emotional behavior whereby they responded
deficiently to fear-conditioning paradigms (Huerta et al., 2006).
The latter has been shown to depend on an intact functionality of
the amygdala (Sengupta et al., 2016).
Beside glutamate receptors, autoimmune phenomena in
CNS involve other receptors, such as leucine-rich glioma
inactivated 1 (LGI1), acquaporin-4 (AQP4), Gamma-Amino
Butyric Acid (GABAB), or myelin oligodendrocyte protein
(MOG; see Irani et al., 2014 for a detailed review). In
preclinical studies, immunization with MOG has been shown,
in susceptible animals, to trigger the onset of a series of
inflammatory diseases and thereafter named experimental
autoimmune encephalomyelitis (EAE). EAE, considered as a
valid animal model of multiple sclerosis (MS), are a group
of pathologies characterized by neurodegeneration, extensive
inflammation and demyelination in CNS. These neurochemical
alterations cause severe progressive motor impairments that
ultimately result in flaccid paralysis of hind limbs (see Kipp
et al., 2012 for a detailed review). Beside MOG (Amor et al.,
1994, 1996), other myelin antigens are capable of triggering
the onset of EAE in rodents, such as myelin basic protein
(MBP, see Swanborg, 2001 and Amor et al., 1996), proteolipid
protein (PLP, see Amor et al., 1993 and Amor et al., 1996)
in presence of increased BBB permeability (Rabchevsky et al.,
1999). Several preclinical studies showed that EAE are associated
not only with severe motor deficits, but also with behavioral
and cognitive impairments (Mandolesi et al., 2010; Acharjee
et al., 2013; Olechowski et al., 2013). For example, Mandolesi
et al. (2010) reported that EAE mice, compared to controls,
showed hippocampal-dependent deficit in learning and memory
(Mandolesi et al., 2010). Similarly, Acharjee and colleagues
observed that EAE mice exhibited cognitive and behavioral
impairments in a precocious phase of the disease (Acharjee
et al., 2013). In particular, EAE mice exhibited reduction in the
time spent in the target quadrant of Morris Water maze and
impaired memory extinction in a fear-conditioning paradigm
(Acharjee et al., 2013). Regarding behavioral impairments,
authors observed in EAE mice increased anxiety-like behaviors.
EAE mice showed, compared to controls, more time in the
marginal zone of the apparatus during open field test and
increased time in the closed arm of plus maze test (Acharjee et al.,
2013). Finally, Olechowski et al. (2013) observed impairments in
cognitive processes (assessed with a novel object recognition test)
in a precocious phase of the disease (Olechowski et al., 2013).
The experimental evidence described above suggests that
autoimmune phenomena against CNS targets may trigger,
in vulnerability conditions, the development of remarkable
phenotypic abnormalities. The appearance of different behavioral
and neurochemical impairments depends on the brain target
affected by the autoimmune phenomena and, in some instances,
by the tools adopted to modulate BBB integrity. As reported
above (see Introduction), analogous mechanisms have been
proposed to contribute to the onset and exacerbation of
streptococcal-related motor disturbances in clinical populations.
Specifically, several authors (Martino et al., 2009; Murphy
et al., 2010) proposed that antibodies produced in response
to streptococcal infections (STREP) may, in presence of an
increased vulnerability of the BBB, induce a pathological
phenotype. In particular, these authors proposed that STREP-
related antibodies may cross the damaged BBB and bind
specific brain targets at the level of Basal Ganglia (BG), a
brain structure involved in motor control. This cascade of
events may ultimately provoke a symptomatology typical of
streptococcal-related motor disturbances. In the next section we
will describe some specific animal models developed with the
aim of dissecting the mechanisms bridging the immunologic
responses to streptococcal infections to the onset of neurological
and behavioral dysfunctions.
A Potential Link between Streptococcal
Infections and TS
Passive Transfer of Sera from TS Patients
Different approaches have been used to develop animal models
addressing the role of streptococcal infections in immune-
mediated neuropsychiatric disorders (Table 1). The first line of
studies entailed direct intracerebral administration, in rats, of
anti-neuronal antibodies sampled from TS patients (Hallett et al.,
2000; Taylor et al., 2002; Loiselle et al., 2004; Singer et al.,
2005b; Ben-Pazi et al., 2012; Yeh et al., 2012). Hallett et al.
(2000) showed that brain intra-striatal microinfusions of TS sera
induced behavioral stereotypies and episodic utterances (EU,
repetitive, medium pitched sound of short duration) in male
Fischer 344 rats. Stereotypies and EUs are considered analogous
to involuntary movements observed in TS patients. In particular,
the authors performed two separate studies, microinfusing either
sera obtained from TS children or Gamma Immunoglobulin
(IgG) isolated from these sera. In the first study, compared to
facility-reared controls, rats microinfused with TS-sera showed
exacerbated licking behavior, forepaw shaking and EU. Those
abnormal behaviors were present during microinfusion, and on
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TABLE 1 | Summary of the main findings in TS/PANDAS animal models.
References Passive transfer (PT) or
direct immunization (DI)
Reference
pathology
Neurochemical/Neuroanatomical
abnormalities
Behavioral outcome
Hallett et al., 2000 PT of sera or purified IgG
from TS patients
TS IgG deposits in striatum (↑) Licking
(↑) Forepaw shacking
(↑) Episodic utterances
Taylor et al., 2002 PT of sera from TS patients TS – (↑) Oral stereotypies
Yeh et al., 2012 PT of sera or purified
anti-HCN4 from TS patients
TS – (↑) Stereotyped tic behavior
Hoffman et al., 2004 DI TS/PANDAS IgG deposits in deep cerebellar nuclei
(DCN)
(↑) Rearing behavior
Yaddanapudi et al., 2010 DI TS/PANDAS IgG deposits in cerebellum and
striatum
(↓) Social activities and social investigation
(↓) Ability in olfactory discrimination
(↓) Motor coordination
(↓) Aggressive behavior
(↑) Rearing behavior
PT of sera from immunized
mice
TS/PANDAS IgG deposits in hippocampus and
paraventricular area
(↑) Rearing behavior
(↓) Social interaction
Macrì et al., 2015 DI TS/PANDAS Inflammation in rostral diencephalon (↓) Pre-pulse inhibition
(↑) Perseveration
Brimberg et al., 2012 DI TS/PANDAS IgG deposits in striatum, thalamus
and frontal cortex
(↓) Motor capacity
(↑) Compulsive behavior
Lotan et al., 2014 DI TS/PANDAS – (↑) Rearing behavior
(↓) Food manipulation
(↓) Fine motor coordination
PT of purified IgG from
immunized rats
TS/PANDAS Co-localized IgG deposits with D1/D2
receptor and SERT in striatum
(↓) Food manipulation
(↓) Fine motor coordination
Summary of the main articles in which an autoimmune hypothesis of motor disturbances has been addressed. We report the immunization method, the reference pathology, the
neuroanatomical, neurochemical, and behavioral alterations identified.
days 8–10 after the end of microinfusion, when behavior was
assessed. EUs were particularly interesting, since rats usually do
not emit audible vocalizations in non-threatening environment
(Kaltwasser, 1990), as the one adopted in this study. The
authors proposed that sudden and involuntary contraction
of respiratory muscles (resulting from the effect of serum
on rats’ striatal functionality) may provoke EU. Furthermore,
these sudden and audible vocalizations occurred in association
with head or oral stereotypies, suggesting that contraction
of respiratory muscles could be involved in their occurrence
(Ebrahimi et al., 1992). In the second study, IgGwas isolated from
both control and TS sera and microinfused into rats’ striatum.
Compared to control individuals, rats microinfused with TS-
IgG exhibited a much higher level of licking activity. Moreover,
immunohistochemical analyses of brain sections showed that
TS-IgG selectively bind striatal neurons in rats microinfused
with TS-IgG. These results supported the hypothesis that IgG
recognize specific neuronal antigens within the striatum and
interfere with its normal functioning, inducing abnormalities
in motor control (Hallett et al., 2000). Similarly, Taylor
et al. (2002) observed an increase in oral stereotypies after
infusions of TS sera into the ventrolateral striatum of male
Sprague-Dawley rats. In this study, the authors performed 5
days of microinfusions and conducted systematic behavioral
observations throughout the entire treatment period. Specifically,
the authors assessed the behavior of three groups of rats, with
different sera received during microinfusion: TS-sera containing
high levels of autoantibodies, TS-sera containing low levels of
autoantibodies and control sera. Rats microinfused with TS-sera
characterized by highest antibody titers exhibited remarkably
elevated oral stereotypies compared to the other groups (Taylor
et al., 2002). Finally, Yeh et al. (2012) showed that TS sera
were immunoreactive against a 120 kDa protein, identified
as hyperpolarization-activated nucleotide channel 4 (HCN4)
protein. Male Sprague-Dawley rats received microinfusion in
striatum of purified anti-HCN4 antibodies and of TS-sera.
Behavioral observation after infusion revealed that both TS
sera and purified anti-HCN4 antibodies induced the increase of
behavioral stereotypies in rats in a dose-dependent manner (Yeh
et al., 2012). Additionally, several studies reported that passive
transfer, in striatum of naïve animals, of anti-streptococcal sera
or of purified IgG from animals exposed to GABHS, leads
to the onset of behavioral and neurochemical abnormalities
that resemble PANDAS symptomatology (Yaddanapudi et al.,
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2010; Lotan et al., 2014). These studies are detailed in the next
section.
Although these results support the existence of a link between
autoimmune phenomena and behavioral stereotypies, analogous
subsequent studies failed to replicate these findings (Loiselle et al.,
2004; Singer et al., 2005b; Ben-Pazi et al., 2012). In particular,
Loiselle et al. (2004) performed microstriatal infusions of serum
from TS and PANDAS patients in Fischer rats’ striatum. In this
study, rats received bilateral microinfusions of sera in ventral and
ventrolateral striatum. As in the experimental protocol described
in Hallett et al. (2000), sera were microinfused for 3 days, and
animal behavior was assessed during microinfusions and for 10
days after the end of microinfusions. Unlike the two studies
previously described (Hallett et al., 2000; Taylor et al., 2002),
rats microinfused with TS sera or PANDAS sera did not show
a significant increase in terms of motor or vocal stereotypies
(Loiselle et al., 2004). Similarly, Singer et al. (2005b) observed that
infusions of sera from patients with TS in ventrolateral striatum
of Sprague-Dawley rats, did not significantly increase stereotypies
(Singer et al., 2005b). A total of 16 rats received (for 4 days)
sera containing elevated or low levels of antineural antibodies
(ANAb), while eight control rats were infused with phosphate
buffered saline (PBS). Behavioral observations were performed
for 3 days before infusions, on days 2–4 during infusions,
and for 3 days after the end of infusions. Stereotypies resulted
significantly increased after serum infusion, but authors did not
observe significant differences between control group and groups
treated with low or elevated ANAb sera. Moreover, in contrast
with Taylor et al. (2002), this study suggests that the level of
antibodies in bloodmay have no influence on their pathogenicity;
low or elevated titers of antineural antibodies in sera did not
induce a differential behavioral response in terms of stereotypies
(Singer et al., 2005b). Finally, Ben-Pazi et al. (2012), did not
observe motor behavioral changes in rats after the injections of
sera from Sydenhams’s Chorea (SC) patients (Ben-Pazi et al.,
2012). In particular, authors injected stereotaxically 6 µl of the
IgG fraction of serum in rats’ left striatum, and induced rotational
behavior administering amphetamine and apomorphine (after
10 and 17 days from injections respectively). Authors observed
that the injections of SC-IgG in rats brain striatum did not
induce a significant increase in rotational behavior. Moreover,
immunohistology staining, specific for dopaminergic or GABA-
ergic markers, did not reveal cellular changes in rats injected
with SDC-IgG compared to controls (Ben-Pazi et al., 2012).
Although the reason for failure to detect stereotypies is unclear,
Loiselle et al. (2004), proposed that methodological variations
may constitute a possible explanation for the variable results
obtained among different studies. These variations comprise
different methods to quantify antineural antibodies in sera, strain
of rodents, timing of microinfusion, timing of observation, and
concentrations of microinfused sera (Loiselle et al., 2004).
Active Immunization with Group A Beta–Hemolytic
Streptococcus Homogenate
Other experimental studies, using a different approach based
on active immunization, reported that streptococcal infections
may trigger, in the presence of a vulnerable BBB, basal ganglia
dysfunctions (Swerdlow and Sutherland, 2005). These studies
show that streptococcus exposure may favor the onset of
behavioral disturbances and neurochemical alterations, thereby
providing additional information regarding PANDAS etiology
(Hoffman et al., 2004; Yaddanapudi et al., 2010; Brimberg
et al., 2012; Macrì et al., 2015). These results may support the
hypothesis that antibodies produced in response to streptococcus
infections may bind, in a context of BBB permeability, brain
targets at the level of basal ganglia, causing the onset of behavioral
and motor disturbances and neurochemical alterations (Martino
et al., 2009).
For example, SJL/J mice (a mouse strain prone to the
induction of autoimmune encephalitis, see Korngold et al.,
1986) repeatedly immunized with a group A beta—hemolytic
streptococcus (GABHS) homogenate emulsified in Freund’s
adjuvant (FA), showed increased behavioral abnormalities
compared to control subjects immunized with FA alone
(Hoffman et al., 2004). Mice were screened in several behavioral
tests to assess anxiety-like behavior, general behavioral responses,
and exploratory behavior. Moreover, sera from all mice
were tested for immunoreactivity to mouse brain, while
the presence of IgG deposits has been assessed performing
immunohistochemistry on cerebral tissues. The authors reported
that a subset of sera collected after the second boost from
GABHS mice were immunoreactive to several brain regions. In
particular, GABHS sera labeled neurons in deep cerebellar nuclei
(DCN), globus pallidus, and thalamus. GABHS immunized
mice, characterized by serum immunoreactivity to DCN, showed
also IgG deposits in the same brain area. Mice that showed
serum immunoreactivity to DCN exhibited also increased
rearing behavior (considered as repetitive behavior) compared
to control mice and to GABHS subjects that did not show
sera immunoreactivity to DCN. Moreover, the increase in
rearing behavior correlated with DCN IgG deposits, and with
serum IgG immunoreactivity to GABHS proteins. These results
partially fulfill the criteria for PANDAS proposed by Swedo
et al. (1998). In particular, the animal model described meets
two criteria: the presence of chronic tic disorder and/or OCD;
and the onset and exacerbation of symptoms associated with
GABHS infections. Mice exposed to GABHS showed abnormal
repetitive behavior, partially reproducing OCD symptomatology
in humans. Moreover, the exhibition of repetitive behavior was
temporally related with the exposure to GABHS (Hoffman et al.,
2004).
In a subsequent study, Yaddanapudi et al. (2010) showed that
humoral immunity is necessary and sufficient to induce PANDAS
related symptoms. The authors passively immunized SJL mice by
exposing them to serum obtained from donor mice immunized
with GABHS homogenate, and observed an abnormal behavioral
phenotype (Yaddanapudi et al., 2010). Direct exposure to
GABHS homogenate resulted in diminishedmotor coordination,
increased rearing behavior, reduced social activities and social
investigation, inhibition of aggressive behavior and impaired
ability in olfactory discrimination. Passive transfer of GABHS
sera reproduced the increment in rearing behavior and the
alteration in social interaction, while did not have effects on
motor coordination. To demonstrate that the effects were due
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to the immune response to the streptococcus immunization,
the authors also performed a passive transfer study in which
sera of donor mice was depleted from Immunoglobulin G.
IgG emerged as the active component of GABHS donor sera
whereby its depletion abolished the behavioral abnormalities
observed in mice injected with non-depleted IgG GABHS
sera. Consistently with what emerged regarding behavioral
observations, donor GABHS mice showed brain IgG deposits in
cerebellum and striatum and mice injected with non-depleted
IgG GABHS sera showed brain IgG deposits in hippocampus
and paraventricular area. Conversely, IgG-depleted GABHSmice
did not show brain deposits, confirming that IgG is the active
component of GABHS sera. The different localization of brain
IgG deposits in donor mice and in mice that received non-
depleted sera, may depend on the different approaches used
to increase the permeability of BBB (Freund’s adjuvant and
LPS respectively). These results, together with what observed
in experimental studies involving animal models of SLE (see
Kowal et al., 2004 and Huerta et al., 2006), suggest that BBB
permeability is crucial inmediating the involvement of peripheral
immunity in PANDAS and, in general, in neuropsychiatric
and neurological disorders (Almutairi et al., 2016). Recently,
Dileepan et al. (2016), proposed a mechanism that allows
antibodies produced in response to streptococcal infections to
cross the BBB and trigger autoimmune diseases of the CNS
(Dileepan et al., 2016). In particular, they reported the presence
of group A streptococcal specific Th17 lymphocytes in tonsils
of humans previously exposed to natural GABHS infections
(Dileepan et al., 2016). Repeated intranasal (i.n.) inoculations
of GABHS in mice triggered the expansion of Th17 cells
and the production of interleukin 17 (IL17), as shown in a
previous study (Dileepan et al., 2011). IL17 causes the damaging
of BBB barrier through the production of reactive oxygen
species (ROS) in endothelial cells (Kebir et al., 2007; Huppert
et al., 2010). Dileepan et al. (2016) repeatedly inoculated mice
i.n. with GABHS to investigate if exposure to streptococcus
induces Th17 GABHS-specific cells enter the mice brain. They
reported that group A streptococcal infections trigger in mice
a lymphocyte Th17 response together with the production of
IL-17A in nasal-associated lymphoid tissue (NALT). NALT is
a tissue located in proximity of cribriform plate and has an
equivalent functionality of palatine tonsils in humans (Park
et al., 2003). Moreover, they reported the presence of GABHS-
specific Th17 cells associated with damaged BBB; the damaged
BBB allowed the deposition of serum IgG. Finally they reported
the presence of activated microglia (neuroinflammation) and
impaired synaptic transmission. The authors suggested that
the abnormal production of cytokine induced by infections
may disrupt the BBB, permitting autoantibodies to access the
brain and bind neural targets, ultimately causing the onset of
pathological phenotypes (Dileepan et al., 2016).
Recently, we repeatedly exposed developing male SJL/J mice
to a GABHS homogenate, showing that a single exposure to
streptococcus is not sufficient to trigger behavioral abnormalities
related to PANDAS (Macrì et al., 2015). In particular, we exposed
mice to a primary immunization (GABHS homogenate
emulsified in CFA), followed by three boosts (GABHS
homogenate emulsified in incomplete Freund’s adjuvant).
We screened mice in two different behavioral test batteries
performed between the primary immunization and the first
boost, and after the second boost. Mice exposed to a single
GABHS immunization did not show a differential phenotype
compared to controls. Conversely, after the second boost,
GABHS mice showed increased repetitive and perseverative
behaviors and impaired sensorimotor gating. To evaluate
sensorimotor gating, we measured their motor response in the
Prepulse Inhibition of the startle reflex (PPI) task. PPI is an
experimental measure in which the startle reflex (response to
sudden and intense stimulus) is inhibited by a weak stimulus.
This task is of common use in human laboratory and holds
an elevated translational value (Swerdlow, 2013). In rodents,
whole-body startle is measured by assessing the force resulting
from the contraction of skeletal muscles (Swerdlow, 2013).
PPI results impaired in a series of neuropsychiatric disorders,
including schizophrenia (Swerdlow et al., 2006), Huntington
disease (Swerdlow et al., 1995; Valls-Sole et al., 2004), OCD
(Swerdlow et al., 1993; Hoenig et al., 2005; Ahmari et al., 2012),
as well as TS (Castellanos et al., 1996; Swerdlow et al., 2001a,b;
Zebardast et al., 2013). Preclinical evidence showed that in
rodents experimental lesions of striatal circuits significantly
reduced PPI (Baldan Ramsey et al., 2011), and that the
administration of dopaminergic drugs modulated its expression
(Mansbach et al., 1988; Russig et al., 2004). Therefore, impaired
PPI observed in GABHS mice supports the hypothesis that
repeated exposures to streptococcus may cause dysfunctions in
cortico-striatal-thalamocortical (CSTC) circuits, involved in TS
(Swerdlow, 2013). A dysfunctional regulation of the CSTC has
been proposed to constitute a common factor among TS and
comorbid problems, such OCD (Berardelli et al., 2003; Leckman
et al., 2010). This hypothesis is supported by clinical evidence
suggesting the involvement of the central dopaminergic system
in TS: tics frequency is increased by dopamine (DA) D2 receptor
agonists (Shprecher and Kurlan, 2009), and reduced by D2
antagonists (Scahill et al., 2006).
The increased perseverative behavior observed in GABHS
mice constitutes an additional evidence supporting the
hypothesis that repeated exposure to streptococcus may
cause dysfunctions in brain areas considered involved in TS.
In particular, we assessed perseverative behavior in T-maze
test to measure spontaneous alternation, considered as a
natural tendency to explore the environment (Deacon and
Rawlins, 2006). Lalonde (2002) showed that the exhibition of
spontaneous alternation depends on the integrity of several
brain areas, including prefrontal cortex and dorsal striatum
(Lalonde, 2002). Moreover, the administration of dopaminergic
and serotoninergic drugs modulates spontaneous alternation
behavior (Irwin et al., 1983; Jaffard et al., 1991).
The fact that behavioral abnormalities have been observed
after repeated exposures to GABHS supports the hypothesis that
a single immunization with streptococcus is not sufficient
to trigger a pathological phenotype. The exhibition of
symptoms may require a prolonged exposure, associated
with the development of a high level of peripheral anti-GABHS
antibodies. This hypothesis is supported by the fact that
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we found elevated concentrations of antibodies in GABHS-
mice sera after repeated injections, but not after the primary
immunization. Mice repeatedly exposed to streptococcus showed
also neurochemical alterations (reduced serotonin and increased
lactate) in prefrontal cortex, a brain structure involved in the
control of the behavioral domains addressed in the study.
Moreover, GABHS mice exhibited inflammatory processes
(presence of infiltrates and active microglia) in the rostral
diencephalon. Thus, our study supports the hypothesis that
exposure to streptococcus is a vulnerability factor in the onset
of behavioral and neurochemical phenotypes homologous to
symptoms observed in PANDAS.
Brimberg et al. (2012) reported that male Lewis rats exposed to
GABHS antigens, showed behavioral, immunological, and neural
characteristics resembling symptoms observed in PANDAS
patients (Brimberg et al., 2012). Rats exposed to GABHS
exhibit impaired motor capacity and compulsive behavior. The
administration of haloperidol and paroxetine, both used to
treat motor symptoms and compulsion in PANDAS, alleviated
symptoms observed in GABHS mice. Importantly, this study
was the first reporting the presence of peripheral autoantibodies
against D1 and D2 receptors following active immunization with
GABHS homogenate. Moreover, GABHS-exposed rats showed
IgG deposits in striatum, thalamus and frontal cortex. This
study supports the link between GABHS exposure and the
development of anti-brain antibodies (in rats sera), specifically
directed against dopamine receptors. This evidence supports the
idea that dopaminergic system has an important role in the
onset of symptoms related to PANDAS (including TS). Finally,
Lotan et al. (2014) extended these results by the identification of
the serotonergic system as an additional mediator of the onset
of PANDAS related symptoms. Specifically, beside replicating
the presence of antibodies against D1 and D2 receptors, they
observed peripheral antibodies against serotonin (5HT-2A and
5HT-2C) receptors in rats previously exposed to GABHS (Lotan
et al., 2014). Furthermore, the active immunization of male
Lewis rats resulted in a series of phenotypic abnormalities
associated with compulsive behavior and motor impairments:
increased grooming; impairments in food manipulation; and
impairments in fine motor activity tested through walking on
a narrow beam (Lotan et al., 2014). These observations are
in line with pharmacological evidence indicating that several
serotonergic agonists may constitute an effective treatment for
the GABHS-dependent psychiatric symptoms (Swedo and Grant,
2005; Murphy et al., 2010). Additionally, these results parallel our
study in whichwe showed that active streptococcal immunization
throughout development may alter serotonergic transmission in
the adult brain (Macrì et al., 2015). In the same study, Lotan et al.
(2014) addressed whether the antibodies produced in response
to GABHS were sufficient to induce an abnormal phenotype. To
investigate this aspect, the authors performed a passive transfer
experiment in which they injected purified IgG from immunized
and control rats directly in the striatum of naïve rats (Lotan
et al., 2014). In accordance with the predictions, microinfusion
of IgG from immunized rats partially reproduced the phenotype
of rats exposed to the direct immunization: impairments in
food manipulation and in beam walking test (Lotan et al.,
2014). Finally, immunoistochemical analysis of IgG deposits in
striatum revealed the presence of IgG clusters in striatum of rats
passively exposed to GABHS; moreover, the authors observed
that these clusters co-localized with D1 and D2 receptors and
with serotonin transporter (SERT; Lotan et al., 2014).
LIMITATIONS OF THE STUDIES AND
FUTURE PERSPECTIVES
In the present manuscript, we aimed at describing
animal models developed to investigate the link between
streptococcus infections and the onset of autoimmune-mediated
neuropsychiatric disorder. Within this framework, animal
models developed using active immunization constitute a valid
tool to investigate the etiological mechanisms of PANDAS and
other related disorders, such as TS. Yet, these animal models
present a series of limitations that need to be addressed in
future experimental studies. Specifically, current experimental
models are limited in terms of the timing of symptoms
observation (prepubertal onset in humans in spite of the fact that
abnormalities in rodents are generally addressed in already adult
subjects) and in the limited exploitation of gene × environment
interactions. In the following section, we discuss these limitations
and propose an approach to overcome them in the future (these
aspects are summarized in Table 2). As briefly mentioned, one
of the core limitations is represented by the timing of the onset
of PANDAS-like phenotype in preclinical models. PANDAS, as
already discussed, are a series of streptococcal-related disorders
that occur specifically in the pediatric population. Most of the
PANDAS-related symptoms observed in animals (stereotypies,
repetitive and perseverative behavior, impaired sensorimotor
gating) have instead been addressed in late adolescent/adult
individuals. Such limitation is predominantly related to technical
constraints associated with the immunization protocol. In all the
studies analyzed, the first immunization of a repeated protocol
has been performed at four (Hoffman et al., 2004; Yaddanapudi
et al., 2010; Macrì et al., 2015), five (Brimberg et al., 2012), or
6 weeks (Hoffman et al., 2004; Yaddanapudi et al., 2010) of
age, corresponding, in rodents, to puberty and adolescence.
Moreover, the subsequent injections (performed to simulate a
repeated exposure to streptococcus) were always interspaced by
3 weeks. Thus, the consequences of the repeated exposure to
streptococcus have been evaluated in fully adult mice. To assess
the effects of streptococcus in younger individuals and come
closer to the specific characteristic of the pediatric population,
future studies shall entail an earlier timing of the primary
injection, and much shorter intervals between boosts.
Animal Models and Gene × Environment
Interactions
With particular attention to TS, the utility of autoimmunemodels
should be extended to investigate the role gene × environment
interactions. Considering themultifactorial and complex etiology
of TS (entailing also genetic vulnerability), several experimental
models leveraged the use of genetically-engineered animals. For
example, SLITRK knockout (ko) mice, have been developed
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TABLE 2 | Experimental models of PANDAS and TS.
Pandas and TS Experimental models of pandas and TS Future perspectives
Chronic tic disorders and/or OCD1 OCD-like behaviors: increased repetitive behaviors,
stereotypies, perseverative behavior and fine
motor coordination4−11
Extension of the behavioral phenotype to
incorporate patterns analogous to tics
Association with streptococcal infections1 Association with streptococcal infections through
active immunization7–11 or passive transfer of sera
from TS patients4–6
Design of complex experimental protocols
entailing a double hit hypothesis (e.g., stress
during pregnancy x streptococcal immunization
early in puberty)
Motor hyperactivity1 Motor hyperactivity Prolongation of the analysis of motor behavior
(e.g., continuous monitoring of behavior
through automated systems)
Prepubertal onset1 Prepubertal onset Earlier administration of streptococcal antigens
Relapsing and remitting course of the disease1 Relapsing and remitting course of the disease –
Impaired PPI2 Impaired PPI9 –
Autoantibodies developed following streptococcal
infections, cross the BBB and bind specific target at the
level of BG, causing morphological alteration in CNS3
IgG deposits in cerebellum, striatum, hippocampus
and paraventricular area7, 8 inflammation in rostral
diencephalon9
Investigation of the role of microglia and
astrocytes in the autoimmune sequelae in
preclinical models12
Bold, Scientific evidence; Italics, hypothesis; Normal text, Clinical evidence not reproduced in animal models.
Numbers indicate the references in which the corresponding information has been described. (1) Swedo et al., 1998; (2) Swerdlow et al., 2001b; (3) Martino et al., 2009; (4) Hallett
et al., 2000; (5) Taylor et al., 2002; (6) Yeh et al., 2012; (7) Hoffman et al., 2004; (8) Yaddanapudi et al., 2010; (9) Macrì et al., 2015; (10) Brimberg et al., 2012; (11) Lotan et al., 2014;
(12) Benedek et al., 2016.
following the identification of mutations in SLITRK genes in
TS patients (Katayama et al., 2010). Although Slitrk1-deficient
mice possess a great degree of construct validity, this model does
not resemble TS symptomatology, thereby possessing a limited
degree of face validity. In particular, Sltrk1 ko mice did not show
tic-like symptoms or neurochemical abnormalities typical of TS.
Other genetic models have been developed based on the link
between TS and glutamatergic hyperactivity inside the CSTC. In
particular, Nordstrom and colleagues developed a D1 receptor
transgenic animal model (D1CT-7), expressing hyperactivity
in two groups of neural populations located (expressing D1
receptors) in the insular and piriform cortices and in the
amygdala (Nordstrom and Burton, 2002). These mice exhibit
features that are analogous to the tics observed in TS patients
(very brief isolated head or body jerk or shake); moreover, these
symptoms are alleviated by the administration of drugs that
have analogous effects in humans. Despite the good degree of
face and predictive validity of this model, D1CT-7 mice exhibit
also features that are not typical of TS (see Macrì et al., 2013
for a detailed review). Recently, Castellan Baldan et al. (2014)
developed an animal model resting upon the observation that the
hdc gene may be involved in TS (Ercan-Sencicek et al., 2010).
Within this framework, the authors developed a line of mice
(hdc ko) lacking histidine decarboxylase, which is necessary to
synthesize histamine (Castellan Baldan et al., 2014). These mice
exhibited a significant increase in behavioral stereotypies after
D-amphetamine injection and a deficit in sensorimotor gating,
reflected in impairments in PPI. Haloperidol pretreatment
mitigated behavioral stereotypies. Moreover, while in the brain
of wild type mice HA concentration increased during the
dark-active phase of the diurnal cycle (Haas et al., 2008) HA
concentration was significantly reduced in left hypothalamus,
striatum and right neocortex of ko mice (Castellan Baldan et al.,
2014). Although daytime striatal DA concentration did not differ
between genotypes, hdc ko mice showed a significant increase in
DA concentration during the active phase of the diurnal cycle,
when HA was increased in wild type mice (Castellan Baldan
et al., 2014). This result further supports the hypothesis that
HA negatively regulates DA (Haas et al., 2008). Finally, ko mice
showed a reduction of D2 + D3 receptor density in striatum,
and an increase of D2 + D3 receptor density in substantia nigra,
suggesting a cellular response to the persistent elevation of DA
(Stanwood et al., 2000). Thus, in the light of the theoretical
framework in which it has been developed (clinical evidence
indicating the importance of HA in TS; Ercan-Sencicek et al.,
2010), the phenotypic alterations observed (motor abnormalities
and impaired sensorimotor gating), and the pharmacological
efficacy of haloperidol (one of the treatments of choice in TS,
Bornstein et al., 1990), this experimental model seems to possess
an elevated degree of construct, face and predictive validity.
Given the limitations of both autoimmune and genetic
models, future attempts should be focused on combining some
of the models previously described, aiming at investigating
gene× environment interactions.
Neonatal Environmental Factors and
Individual Vulnerability to PANDAS
Future efforts should be focused also on investigating the
possibility that neonatal environmental factors may calibrate,
and eventually suppress, individual vulnerability to PANDAS.
Several studies reported that precocious experiences affect the
individual resilience toward future challenges (Heim et al.,
2004, 2008; Lyons and Macrì, 2011). In particular, while
traumatic precocious experiences result in increased individual
vulnerability to future challenges (Heim et al., 2004, 2008),
stimulating early conditions have been proposed to favor
individual resilience (Lyons and Macrì, 2011). The immune
system is particularly sensitive to early experiences (Roque
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et al., 2014). For example, several studies conducted in rodents
showed that maternal separation (daily 3–6 h mother-offspring
separations during the first 2 weeks of life) or exposure to
early physiological stressors result in increased susceptibility
toward viral infections (Meagher et al., 2010) or vulnerability
toward autoimmune phenomena (Bakker et al., 2000). Individual
reactivity to immune challenge has been proposed to depend
on the functionality of hypothalamic-pituitary-adrenocortical
(HPA) axis (Bakker et al., 2000; Meagher et al., 2010). In
particular, the differential response to immune challenge depends
on the modulation of the functionality of immune system exerted
by elevations in levels of corticosterone (Laban et al., 1995).
Several studies showed that circulating corticosteroids have a
direct effect on T-cell, suppressing immune responses (Wick
et al., 1993). Thus, it is tenable to propose that the modulation
of corticosterone reactivity through experimental stressors, may
calibrate individual susceptibility toward phenomena that relate
to immunity (immune and autoimmune phenomena). Within
this framework, Levine and Saltzman (1987) reported that
experimental stressors favoring an upregulation of the HPA-
axis alter individual vulnerability to EAE (Levine and Saltzman,
1987). Moreover, Levine and colleagues showed that stress
reduces (Levine et al., 1962a) and adrenalectomy enhances
(Levine et al., 1962b) vulnerability to EAE. Thus, a persistent
upregulation of HPA axis induced by neonatal stressor may
consistently prevent some of the consequences of experimental
models of autoimmunity, such as PANDAS. Beside analyzing the
role of environmental factors in modulating the functionality
of the immune system, future studies shall thoroughly detail
which portions of the immune system are involved in the
autoimmune sequelae (Benedek et al., 2016). An interesting
target to be contemplated in future studies is the activation of
microglia and the role exerted by astrocytes (Benedek et al., 2016;
Lécuyer et al., 2016). These targets appear particularly relevant
whereby their involvement has already been demonstrated in
experimental models of autoimmunity (Correale, 2014; Shemer
and Jung, 2015; Benedek et al., 2016; Lécuyer et al., 2016). While
these studies addressed the role of astrocytes and microglia in
experimental models of MS, it may be important to evaluate
whether these outcomes translate to experimental models of
PANDAS or TS. This need is also corroborated by clinical
evidence indicating that microglia can be activated in TS and
PANDAS patients (Kumar et al., 2015), see below for a detailed
description.
Peripheral Autoantibodies As Diagnostic
Biomarker in TS
Finally, we emphasize the value of the detection of peripheral
autoantibodies as a reliable method potentially aiding the
diagnosis of neurological disorders. The search of biological
markers measurable and detectable using non-invasive
approaches constitutes an important tool in the diagnosis
of these diseases (Damoiseaux et al., 2015). With particular
attention to autoimmune disorders, the measurement of
autoantibodies has been proposed as a valuable tool not only in
the diagnosis, but also in the prediction and in the prognosis of
autoimmune diseases (Harel and Shoenfeld, 2006; Shepshelovich
and Shoenfeld, 2006; Bizzaro et al., 2007; see Damoiseaux et al.,
2015 for a detailed review). Within this framework, several
peripheral autoantibodies emerged as clinically relevant in
several neurological and neuropsychiatric disorders, such as
multiple sclerosis (Comabella and Montalban, 2014), limbic
encephalitis (Beck et al., 2009; Schlumberger et al., 2014),
myasthenia gravis (Verschuuren et al., 2013), or ADHD (Giana
et al., 2015). However, the debate on the efficacy of serum
autoantibodies as diagnostic markers is still open. For example
Höftberger (2015) reported that in the case of autoimmune
encephalitis (AIE), serum did not contain antineural antibodies
in the 14% of patients, while autoantibodies were always
detected in patients’ cerebrospinal fluid (CSF). Thus, the
absence of autoantibodies in serum may not be sufficient to
exclude AIE (Höftberger, 2015). With respect to TS, as already
discussed (see Introduction), several clinical studies reported
the presence of anti-BG antibodies in sera of TS patients (Rizzo
et al., 2006; Martino et al., 2011). Moreover, the injections
of TS sera (containing autoantibodies) directly into rodents’
striatum, result, in some cases, in behavioral and neurochemical
alterations that partially resemble PANDAS symptomatology
(Hallett et al., 2000; Yeh et al., 2012). In addition, autoantibodies
in TS sera seem to induce PANDAS-like behavioral phenotypes
in a concentration-dependent manner (high or low level of
autoantibodies titers, see Taylor et al., 2002). These results seem
to support the hypothesis that anti-BG antibodies may constitute
a valid biomarker in the diagnosis of some cases of TS. However,
results reported in subsequent studies, where the passive transfer
of TS sera in rodents’ striatum failed to induce PANDAS-like
phenotypes (Loiselle et al., 2004; Ben-Pazi et al., 2012), suggest
that additional studies are necessary to investigate the diagnostic
value of the detection of peripheral BG-antigens in TS. Further
efforts may be focused, for example, on the standardization
of the assays used to quantify antineural antibodies in sera
(Jacobs et al., 2015). In particular, further studies should be
focused on investigating the use of immunohistochemistry as
a method for the detection of anti-neuronal autoantibodies in
CNS disorders. Hachiya et al. (2013) showed, in a recent study,
that immunohistochemistry may constitute a reliable method
for the detection of autoantibodies in serum of patients affected
by CNS disorders associated with GABHS infections (Hachiya
et al., 2013). In particular, they assessed immunoreactivity of
sera (obtained during the acute phase of disease or during
remission or convalescence) from patients affected by three
CNS disorders linked to GABHS infections (acute disseminated
encephalomyelitis, PANDAS and subacute encephalitis). The
authors performed immunohistochemistry on brain sections
of hippocampus, basal ganglia, cerebellar cortex and midbrain
obtained from male controls (aged 5 and 9 years) that did
not present CNS alterations. Sera obtained from patients
affected by acute disseminated encephalomyelitis and PANDAS
showed immunoreactivity in globus pallidus neurons, while
sera obtained from patients affected by subacute encephalitis
showed immunoreactivity in the extra pyramidal cell layers
in the temporal cortex. Conversely, sera obtained during
remission or convalescence did not show immunoreactivity
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(Hachiya et al., 2013). With particular attention to PANDAS
and TS, future efforts should be focused, for example, on
analyzing immunoreactivity of sera from patients toward
dopamine D2 receptors. In the context of the identification of
immune-related diagnostic biomarkers, Kumar et al. (2015)
recently evaluated neuroinflammation in TS and PANDAS
children. Specifically, the authors performed a Positron Emission
Tomographic (PET) study to identify markers of activated
microglia (Kumar et al., 2015). Activated microglia has been
proposed to constitute a valid indicator of the presence of
neuroinflammation (Kreutzberg, 1996). To address this aspect,
the authors exploited the capacity of activated microglia to
express the translocator protein receptor (TSPO). TSPO, in turn,
can be selectively identified through the radioactive tracer 11C-
[R]-PK11195 (PK) (Cagnin et al., 2007). Using this approach,
the authors analyzed neuroinflammation in basal ganglia and
thalamus and observed increased binding potential in bilateral
caudate and bilateral lentiform nucleus in PANDAS patients.
TS children exhibited neuroinflammation in bilateral lentiform
nucleus only, suggesting possible neuroanatomical differences
between PANDAS and TS diseases (Kumar et al., 2015). Thus, the
monitoring of neuroinflammation through PET may constitute
a potential method to clarify pathophysiological mechanisms in
TS and PANDAS.
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